-
Predicted Top 5 Worldwide Selling Generic or Biosimilar Drugs in 2025
David Orchard-Webb
July 08, 2025
The global pharmaceutical market is approaching a phase in which several high-revenue medicines will lose patent protection, paving the way for generic and biosimilar competition (Scheckel, 2021).
-
Beyond Antibiotics: The Expanding Role of Anti-Infective APIs in Bacterial Infection
Suzanne Elvidge
June 13, 2025
Beyond antibiotics??, novel anti-infective approaches include ??AMPs?? targeting biofilms, ??FMT capsules?? ,nanoparticle delivery systems??, and ??synbiotics?? to combat the global ??AMR crisis??.
-
Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug
Kevin
April 28, 2025
PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.
-
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field?
Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
-
The Race to Reinvent Antibiotics: Why Innovation and Access Must Go Hand in Hand
Neeta Ratanghayra
April 09, 2025
Register to Download PPT and View Why Innovation and Access Must Go Hand in Hand
-
The Global Alpha-Glucosidase Inhibitor Market: Trends and Prospects
David Orchard-Webb
March 18, 2025
Alpha-glucosidase inhibitors are used for type 2 diabetes. This article analyzes their market, including growth, segments, and challenges.
-
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified?
Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
-
Microbiome Impact on Drug Response and Personalized Medicine
Nurah Ekhlaque
February 18, 2025
The gut microbiome impacts drug response and disease management. It affects drug metabolism, efficacy, and toxicity, and is crucial for personalized medicine.
-
The Role of Biosimilars
Suzanne Elvidge
February 12, 2025
Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.
-
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion
Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.